Developer docs
API playgroundTry for free, no card

Search company profiles

Compumedics

Full company profile

uuid00075pz

Namestring
Compumedics
Legal namestring
Compumedics Limited
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Compumedics Limited (ASX: CMP) is a Melbourne-based medical device company founded in 1987 that designs, manufactures, and commercializes diagnostic technology across three core verticals: sleep diagnostics, neurology diagnostics, and brain research. The company operates a hardware-plus-software platform built around proprietary amplifiers and signal acquisition systems (including the Orion LifeSpan MEG with patented DROS SQUID sensors, the Grael 4K PSG:EEG amplifier, Somté ambulatory recorders, Okti portable EEG, and the Somfit wearable sensor), layered with a software stack (Profusion Sleep/EEG, CURRY multimodal neuroimaging suite, and Profusion neXus 360 cloud-based lab management). The portfolio is FDA-cleared, CE-marked, and TGA-cleared for clinical use and is sold via direct enterprise field sales through wholly-owned offices in Australia, the United States, Germany, and France, complemented by distributor arrangements in China and other regions.

The company's revenue model is anchored on capital equipment sales (large systems such as the Orion LifeSpan MEG sell at approximately AUD 4.2 million per unit), recurring software subscriptions and cloud hosting via neXus 360, consumables and electrode/supply sales, and professional services for pharmaceutical clinical trials. Customer segmentation is vertical, with primary end markets being hospital sleep labs and neurology departments, university and research institutions conducting brain imaging research, pharmaceutical sponsors and CROs using EEG endpoints in trials, and emerging applications in sports/military traumatic brain injury screening. The company invests over 15% of revenue in R&D and maintains a 30-year technical collaboration with the Korean Research Institute of Standards and Science (KRISS) underpinning its MEG franchise.

Compumedics is publicly listed on the ASX since 2000, has a global workforce of 101–250 employees, and operates through subsidiaries including Compumedics USA Inc., Compumedics Germany GmbH (DWL), Compumedics Europe GmbH (Neuroscan), and Compumedics France SAS. Leadership is founder-led, with David Burton as Founder, CEO, and Executive Chairman. As of October 2025 the company requested a trading halt pending a capital raising announcement, indicating active use of public equity markets to fund expansion, particularly its China MEG pipeline where it has reported approximately AUD 30 million in contracted MEG orders across six systems.

Short descriptiontext

Compumedics (ASX: CMP) designs, manufactures, and commercializes medical diagnostic devices and software for sleep, neurology, and brain research, serving hospitals, research institutions, pharmaceutical companies, and emerging sports/military TBI markets through direct sales offices across Australia, the United States, Germany, and France.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sleep diagnostic devices, EEG monitoring systems, magnetoencephalography equipment, polysomnography amplifiers, neuroimaging software
Industry4 codes
1Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
CodeHLAHACAEPrimaryYes
2Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
CodeHLAHAGABPrimaryNo
3Sleep Tech Wearables
CodeCRACAIAGPrimaryNo
4Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
CodeHLALAFAJPrimaryNo
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Diagnostic Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Hardware Sales
TypeHardware Sales
Description

Sale of diagnostic medical devices including MEG systems, PSG amplifiers, EEG amplifiers, sleep recorders, and accessories. Major orders include MEG systems at approximately AUD $4.2 million per unit. Products sold directly and through distributors.

compumedics.com.au
2Software Licensing and Subscriptions
TypeSubscription Recurring
Description

Software products including Profusion Sleep, Profusion EEG, Profusion neXus 360, CURRY software. Cloud-based services through neXus 360 hosting. Version updates and support services.

compumedics.com.au
3Supplies and Consumables
TypeHardware Sales
Description

Sale of supplies including electrodes, electrode caps, sensors, accessories, and consumable products for diagnostic systems.

compumedics.com.au
4Pharmaceutical Clinical Trial Support
TypeProfessional Services
Description

Comprehensive support services for pharmaceutical clinical trials including EEG as endpoint measurements, remote monitoring, data management, and regulatory compliance support.

compumedics.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1Enterprise medical equipment pricing - custom quotes for hospitals and research institutions
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; requires direct inquiry through sales channels. Large diagnostic systems (MEG, EEG, PSG) sold as complete solutions with associated software and support packages.

compumedics.com.au
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Somfit
Description

Wearable device for collecting patients' physiological data, primarily for sleep disorder diagnosis

compumedics.com.au
+9 more records
Core offering1 text field

Compumedics designs, manufactures, and commercializes medical diagnostic technology for sleep disorders, neurology, and brain research. Its hardware portfolio includes magnetoencephalography (MEG) systems (Orion LifeSpan), polysomnography (PSG) and EEG amplifiers (Grael 4K, Somté, Siesta 802, Okti, Neuvo), home sleep testing devices (Falcon HST), wearable sensors (Somfit), ambulatory video-EEG monitors (ONsight), and transcranial Doppler systems. Its software portfolio spans the Profusion sleep/EEG analysis suite, the Profusion neXus 360 cloud-based lab management platform, and the CURRY multimodal neuroimaging suite.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% helium recycling enables 24/7 continuous MEG operation with no downtime
+3 more records
Product overview1 text field

Compumedics designs and manufactures medical technology for sleep diagnostics, neurology diagnostics, and brain research. The company operates a platform-plus-modules architecture centered on proprietary amplifiers and software. The hardware portfolio includes MEG systems (Orion LifeSpan), PSG/EEG amplifiers (Grael 4K, Somté, Siesta 802, Okti), and specialized devices (Falcon HST for home sleep testing, Somfit wearable sensor, ONsight video-EEG, DWL TBI detector). The software platform comprises Profusion EEG/Sleep, Profusion neXus 360 lab management, and CURRY neuroimaging suite. Key sub-brands include Compumedics Neuroscan (research/brain research) and Compumedics DWL (transcranial Doppler). The company has invested over 15% of revenues in R&D and holds multiple regulatory clearances including FDA, CE Mark, and TGA. Founded in 1987, Compumedics is listed on the Australian Securities Exchange (ASX: CMP) with global operations across Australia, USA, Germany, and France.

Product and service20 records
1Orion LifeSpan MEG
CategoryMEG / Brain Imaging Hardware
Description

Magnetoencephalography (MEG) brain functional imaging system with patented DROS SQUID sensors, dual-helmet operation for adult and pediatric populations, 100% helium recycling enabling 24/7 continuous operation, and integration with CURRY neuroimaging software. Supports high-density EEG up to 256 channels. Sold primarily to research institutions at approximately AUD 4.2 million per unit.

2Grael 4K PSG:EEG
CategoryPSG/EEG Amplifier
Description

World's first 4K High Definition dual-platform PSG:EEG amplifier with 24-bit resolution, DC-coupled inputs, integrated Power over Ethernet, and wireless connectivity for sleep and neurological diagnostics. Used in hospitals and sleep clinics for combined sleep and EEG studies.

3Grael PSG
4Grael 4K-EEG
5Grael LT EEG System
6Neuvo 64-512 Channel LTM EEG
7Somté PSG
8Somté
9Siesta 802
10Okti
CategoryPortable EEG Amplifier
Description

First high-definition portable EEG amplifier with interchangeable modules (32, 64, 128 channels), wireless enterprise WiFi connectivity, hot-swappable batteries, and patented electrode illumination indicators for rapid patient setup.

11Falcon HST
CategoryHome Sleep Testing Device
Description

Home sleep testing device with unmatched simplicity and clinical precision, featuring cloud/local deployment options, reusable/disposable sensor kits, and integrated ProDigi scoring via Nexus 360.

12Somfit / Somfit Pro
13ONsight A.V.S.
14DWL Traumatic Brain Injury (TBI) Device
15CURRY Neuroimaging Suite
16Profusion EEG Software
CategoryEEG Analysis Software
Description

Clinical EEG software with Microsoft Ribbon interface, supporting up to 45 days continuous recording, high sample rates (up to 10kHz), EDF+ export, and video-EEG synchronization for epilepsy monitoring.

17Profusion Sleep Software
CategorySleep Analysis Software
Description

Sleep analysis software suite with AASM V2 compliance, modern user interface, respiratory band phase analysis, and comprehensive report generation for sleep laboratories.

18Profusion neXus 360
19Transcranial Doppler Sonography (TCD) - Compumedics DWL
CategoryTranscranial Doppler Ultrasound Systems
Description

Transcranial Doppler ultrasound systems for cerebral blood flow monitoring using fully-Doppler sonography with M-Mode, provided through the Compumedics DWL subsidiary based in Singen, Germany.

20Pharmaceutical Clinical Trials & Research Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Beijing Fistar
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-29
Description

Beijing Fistar serves as the distributor for Compumedics MEG systems in China, facilitating sales to Chinese research institutions including Shandong Normal University. The partnership enabled the AUD 4.2 million Orion LifeSpan MEG order.

channellife.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

30-year collaboration with KRISS MEG team led by Dr. Yong-Ho Lee to develop the Orion LifeSpan MEG system with patented DROS SQUID sensor technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natus Medical is one of the closest direct competitors to Compumedics, offering a broad portfolio of neurodiagnostic (EEG, LTM, ICU monitoring) and sleep-diagnostic (PSG, HST) hardware and software used by the same hospital and clinical customers.

TypeDirect peer
Description

MEGIN is the primary global competitor in magnetoencephalography (MEG) systems, the same niche occupied by Compumedics' Orion LifeSpan platform, serving brain-research and clinical neuroscience customers.

TypeDirect peer
Description

Cadwell designs and sells EEG, PSG, and intraoperative neuro-monitoring systems to hospitals and sleep labs, directly overlapping Compumedics' neurology and sleep diagnostics amplifier portfolios.

TypeDirect peer
Description

Nox Medical specialises in PSG and home sleep testing devices and software (Noxturnal), competing head-to-head with Compumedics' Grael, Somté and Falcon HST products in sleep labs and research settings.

TypeBroad incumbent
Description

Nihon Kohden is a larger, established player in clinical EEG, patient monitoring and polysomnography, with global distribution that overlaps Compumedics' clinical neurodiagnostic and PSG amplifier businesses.

TypeBroad incumbent
Description

Philips offers a broad sleep-diagnostics and respiratory-care portfolio (including Alice PSG) targeting the same hospital and sleep-centre customers as Compumedics, but as part of a much wider medtech franchise.

TypeBroad incumbent
Description

ResMed is a global leader in sleep apnea diagnosis and therapy, operating adjacent home sleep testing and consumer sleep health offerings that overlap Compumedics' Somfit and Falcon HST businesses.

TypeBroad incumbent
Description

Medtronic is named alongside Compumedics in third-party brain-monitoring market research and competes broadly in neurology and brain diagnostics through its larger hospital channel and capital equipment business.

TypeEmerging player
Description

Wave Neuroscience applies MEG-based brain-activity analysis in clinical and research settings, partially overlapping Compumedics' MEG and neuroimaging analysis offering but with a more concentrated therapy/treatment orientation.

TypeOthers
Description

Persyst provides EEG analysis and seizure-detection software that Compumedics resells/distributes alongside its Profusion EEG platform; not a direct competitor but an ecosystem partner in the same neurology diagnostics workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Compumedics

Medical Diagnostic Devicescompumedics.com.au

Compumedics (ASX: CMP) designs, manufactures, and commercializes medical diagnostic devices and software for sleep, neurology, and brain research, serving hospitals, research institutions, pharmaceutical companies, and emerging sports/military TBI markets through direct sales offices across Australia, the United States, Germany, and France.

What Compumedics does

Compumedics Limited (ASX: CMP) is a Melbourne-based medical device company founded in 1987 that designs, manufactures, and commercializes diagnostic technology across three core verticals: sleep diagnostics, neurology diagnostics, and brain research. The company operates a hardware-plus-software platform built around proprietary amplifiers and signal acquisition systems (including the Orion LifeSpan MEG with patented DROS SQUID sensors, the Grael 4K PSG:EEG amplifier, Somté ambulatory recorders, Okti portable EEG, and the Somfit wearable sensor), layered with a software stack (Profusion Sleep/EEG, CURRY multimodal neuroimaging suite, and Profusion neXus 360 cloud-based lab management). The portfolio is FDA-cleared, CE-marked, and TGA-cleared for clinical use and is sold via direct enterprise field sales through wholly-owned offices in Australia, the United States, Germany, and France, complemented by distributor arrangements in China and other regions.

The company's revenue model is anchored on capital equipment sales (large systems such as the Orion LifeSpan MEG sell at approximately AUD 4.2 million per unit), recurring software subscriptions and cloud hosting via neXus 360, consumables and electrode/supply sales, and professional services for pharmaceutical clinical trials. Customer segmentation is vertical, with primary end markets being hospital sleep labs and neurology departments, university and research institutions conducting brain imaging research, pharmaceutical sponsors and CROs using EEG endpoints in trials, and emerging applications in sports/military traumatic brain injury screening. The company invests over 15% of revenue in R&D and maintains a 30-year technical collaboration with the Korean Research Institute of Standards and Science (KRISS) underpinning its MEG franchise.

Compumedics is publicly listed on the ASX since 2000, has a global workforce of 101–250 employees, and operates through subsidiaries including Compumedics USA Inc., Compumedics Germany GmbH (DWL), Compumedics Europe GmbH (Neuroscan), and Compumedics France SAS. Leadership is founder-led, with David Burton as Founder, CEO, and Executive Chairman. As of October 2025 the company requested a trading halt pending a capital raising announcement, indicating active use of public equity markets to fund expansion, particularly its China MEG pipeline where it has reported approximately AUD 30 million in contracted MEG orders across six systems.

Compumedics firmographics

Firmographics
Name
Compumedics
Legal name
Compumedics Limited
Website
https://compumedics.com.au
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
101–250 employees
Short description
Compumedics (ASX: CMP) designs, manufactures, and commercializes medical diagnostic devices and software for sleep, neurology, and brain research, serving hospitals, research institutions, pharmaceutical companies, and emerging sports/military TBI markets through direct sales offices across Australia, the United States, Germany, and France.
Ownership category
akta.pro rank

Compumedics industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
akta.pro secondary industries
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB), Sleep Tech Wearables (CRACAIAG), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

Keywords

  • Sleep diagnostic devices
  • EEG monitoring systems
  • Magnetoencephalography equipment
  • Polysomnography amplifiers
  • Neuroimaging software

Where Compumedics is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices5 records

Markets served

Compumedics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Hardware Sales: Sale of diagnostic medical devices including MEG systems, PSG amplifiers, EEG amplifiers, sleep recorders, and accessories. Major orders include MEG systems at approximately AUD $4.2 million per unit. Products sold directly and through distributors.
  2. Software Licensing and Subscriptions: Software products including Profusion Sleep, Profusion EEG, Profusion neXus 360, CURRY software. Cloud-based services through neXus 360 hosting. Version updates and support services.
  3. Supplies and Consumables: Sale of supplies including electrodes, electrode caps, sensors, accessories, and consumable products for diagnostic systems.
  4. Pharmaceutical Clinical Trial Support: Comprehensive support services for pharmaceutical clinical trials including EEG as endpoint measurements, remote monitoring, data management, and regulatory compliance support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise medical equipment pricing - custom quotes for hospitals and research institutions

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Compumedics product offering

Product offering

Core offering

Compumedics designs, manufactures, and commercializes medical diagnostic technology for sleep disorders, neurology, and brain research. Its hardware portfolio includes magnetoencephalography (MEG) systems (Orion LifeSpan), polysomnography (PSG) and EEG amplifiers (Grael 4K, Somté, Siesta 802, Okti, Neuvo), home sleep testing devices (Falcon HST), wearable sensors (Somfit), ambulatory video-EEG monitors (ONsight), and transcranial Doppler systems. Its software portfolio spans the Profusion sleep/EEG analysis suite, the Profusion neXus 360 cloud-based lab management platform, and the CURRY multimodal neuroimaging suite.

Product overview

Compumedics designs and manufactures medical technology for sleep diagnostics, neurology diagnostics, and brain research. The company operates a platform-plus-modules architecture centered on proprietary amplifiers and software. The hardware portfolio includes MEG systems (Orion LifeSpan), PSG/EEG amplifiers (Grael 4K, Somté, Siesta 802, Okti), and specialized devices (Falcon HST for home sleep testing, Somfit wearable sensor, ONsight video-EEG, DWL TBI detector). The software platform comprises Profusion EEG/Sleep, Profusion neXus 360 lab management, and CURRY neuroimaging suite. Key sub-brands include Compumedics Neuroscan (research/brain research) and Compumedics DWL (transcranial Doppler). The company has invested over 15% of revenues in R&D and holds multiple regulatory clearances including FDA, CE Mark, and TGA. Founded in 1987, Compumedics is listed on the Australian Securities Exchange (ASX: CMP) with global operations across Australia, USA, Germany, and France.

Differentiator

Problem solved

Functional benefit

Brands

  • Somfit: Wearable device for collecting patients' physiological data, primarily for sleep disorder diagnosis
  • Grael
  • Somté
  • Profusion
  • CURRY
  • Orion LifeSpan
  • Falcon HST
  • Neuvo
  • Okti
  • ONsight A.V.S.

Products and services

  • Orion LifeSpan MEG Magnetoencephalography (MEG) brain functional imaging system with patented DROS SQUID sensors, dual-helmet operation for adult and pediatric populations, 100% helium recycling enabling 24/7 continuous operation, and integration with CURRY neuroimaging software. Supports high-density EEG up to 256 channels. Sold primarily to research institutions at approximately AUD 4.2 million per unit.
  • Grael 4K PSG:EEG World's first 4K High Definition dual-platform PSG:EEG amplifier with 24-bit resolution, DC-coupled inputs, integrated Power over Ethernet, and wireless connectivity for sleep and neurological diagnostics. Used in hospitals and sleep clinics for combined sleep and EEG studies.
  • Grael PSG
  • Grael 4K-EEG
  • Grael LT EEG System
  • Neuvo 64-512 Channel LTM EEG
  • Somté PSG
  • Somté
  • Siesta 802
  • Okti First high-definition portable EEG amplifier with interchangeable modules (32, 64, 128 channels), wireless enterprise WiFi connectivity, hot-swappable batteries, and patented electrode illumination indicators for rapid patient setup.
  • Falcon HST Home sleep testing device with unmatched simplicity and clinical precision, featuring cloud/local deployment options, reusable/disposable sensor kits, and integrated ProDigi scoring via Nexus 360.
  • Somfit / Somfit Pro
  • ONsight A.V.S.
  • DWL Traumatic Brain Injury (TBI) Device
  • CURRY Neuroimaging Suite
  • Profusion EEG Software Clinical EEG software with Microsoft Ribbon interface, supporting up to 45 days continuous recording, high sample rates (up to 10kHz), EDF+ export, and video-EEG synchronization for epilepsy monitoring.
  • Profusion Sleep Software Sleep analysis software suite with AASM V2 compliance, modern user interface, respiratory band phase analysis, and comprehensive report generation for sleep laboratories.
  • Profusion neXus 360
  • Transcranial Doppler Sonography (TCD) - Compumedics DWL Transcranial Doppler ultrasound systems for cerebral blood flow monitoring using fully-Doppler sonography with M-Mode, provided through the Compumedics DWL subsidiary based in Singen, Germany.
  • Pharmaceutical Clinical Trials & Research Services

Quantifiable outcome

  • 100% helium recycling enables 24/7 continuous MEG operation with no downtime
  • +3 more outcomes

Companies that use Compumedics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Compumedics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Compumedics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Beijing FistarcoreChannel Partner/ Reseller/ Distributor · 29 January 2026Beijing Fistar serves as the distributor for Compumedics MEG systems in China, facilitating sales to Chinese research institutions including Shandong Normal University. The partnership enabled the AUD 4.2 million Orion LifeSpan MEG order.
  • Korean Research Institute of Standards and Science (KRISS)coreStrategic or Co-development Partner30-year collaboration with KRISS MEG team led by Dr. Yong-Ho Lee to develop the Orion LifeSpan MEG system with patented DROS SQUID sensor technology.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Compumedics competitors and assessment

Company assessment

Direct peers

  • Natus Medical: Natus Medical is one of the closest direct competitors to Compumedics, offering a broad portfolio of neurodiagnostic (EEG, LTM, ICU monitoring) and sleep-diagnostic (PSG, HST) hardware and software used by the same hospital and clinical customers.
  • MEGIN (formerly Elekta MEG): MEGIN is the primary global competitor in magnetoencephalography (MEG) systems, the same niche occupied by Compumedics' Orion LifeSpan platform, serving brain-research and clinical neuroscience customers.
  • Cadwell Industries: Cadwell designs and sells EEG, PSG, and intraoperative neuro-monitoring systems to hospitals and sleep labs, directly overlapping Compumedics' neurology and sleep diagnostics amplifier portfolios.
  • Nox Medical: Nox Medical specialises in PSG and home sleep testing devices and software (Noxturnal), competing head-to-head with Compumedics' Grael, Somté and Falcon HST products in sleep labs and research settings.

Broad incumbents

  • Nihon Kohden: Nihon Kohden is a larger, established player in clinical EEG, patient monitoring and polysomnography, with global distribution that overlaps Compumedics' clinical neurodiagnostic and PSG amplifier businesses.
  • Philips (Sleep & Respiratory): Philips offers a broad sleep-diagnostics and respiratory-care portfolio (including Alice PSG) targeting the same hospital and sleep-centre customers as Compumedics, but as part of a much wider medtech franchise.
  • ResMed: ResMed is a global leader in sleep apnea diagnosis and therapy, operating adjacent home sleep testing and consumer sleep health offerings that overlap Compumedics' Somfit and Falcon HST businesses.
  • Medtronic: Medtronic is named alongside Compumedics in third-party brain-monitoring market research and competes broadly in neurology and brain diagnostics through its larger hospital channel and capital equipment business.

Emerging players

  • Wave Neuroscience: Wave Neuroscience applies MEG-based brain-activity analysis in clinical and research settings, partially overlapping Compumedics' MEG and neuroimaging analysis offering but with a more concentrated therapy/treatment orientation.

Others

  • Persyst Development Corporation: Persyst provides EEG analysis and seizure-detection software that Compumedics resells/distributes alongside its Profusion EEG platform; not a direct competitor but an ecosystem partner in the same neurology diagnostics workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compumedics social profiles

Digital presence

Compumedics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Compumedics leadership team

Management profile

Number of profiles

Profiles3 records

Compumedics subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Compumedics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Compumedics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compumedics

What does Compumedics do?

Compumedics designs, manufactures, and commercializes medical diagnostic technology for sleep disorders, neurology, and brain research. Its hardware portfolio includes magnetoencephalography (MEG) systems (Orion LifeSpan), polysomnography (PSG) and EEG amplifiers (Grael 4K, Somté, Siesta 802, Okti, Neuvo), home sleep testing devices (Falcon HST), wearable sensors (Somfit), ambulatory video-EEG monitors (ONsight), and transcranial Doppler systems. Its software portfolio spans the Profusion sleep/EEG analysis suite, the Profusion neXus 360 cloud-based lab management platform, and the CURRY multimodal neuroimaging suite.

Is Compumedics a public or private company?

Compumedics is a public company. It is classified as public and is currently operating.

When was Compumedics founded?

Compumedics was founded in 1987. It employs 101 to 250 people.

Where is Compumedics based?

Compumedics is headquartered in Melbourne, Australia, in the Oceania region.

How does Compumedics make money?

Four revenue lines are on record. Medical Hardware Sales are the primary driver. The others are software Licensing and Subscriptions, supplies and Consumables and pharmaceutical Clinical Trial Support.

Who are Compumedics's main competitors?

Direct peers on record are Natus Medical, MEGIN (formerly Elekta MEG), Cadwell Industries and Nox Medical. Broad incumbents are Nihon Kohden, Philips (Sleep & Respiratory), ResMed and Medtronic. Wave Neuroscience is listed as an emerging player. Persyst Development Corporation is listed as an others.

Does Compumedics have an API?

No public API is recorded for Compumedics.

What industry is Compumedics in?

Compumedics's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CfotechCompumedics posts record revenue as profit turns positiveCompumedics reported FY26 revenue of AUD $60.3 million, up 18.5%, with EBITDA of AUD $5.4 million, up 72.1%, and net profit after tax of AUD $0.2 million. Operating cash inflow rose to AUD $6.6 million and cash and equivalents to AUD $5.6 million. The company targets double-digit revenue growth in FY27 with EBITDA growth outpacing revenue.KalkineWhy Compumedics (ASX:CMP) Shares Under Pressure- What the FY26 Result Signals?Compumedics reported record FY2026 revenue of approximately A$60 million but saw its shares drop 8.33% as the results fell short of revised market expectations due to timing delays in MEG system shipments and a slower-than-expected US rollout of its Somfit platform. The company cited helium supply constraints affecting hardware deliveries, while highlighting recurring software revenue growth from platforms like Nexus 360 as a key long-term earnings driver. Investors are now monitoring future guidance and execution risks related to product launches and supply chain stability.KalkineCompumedics (ASX:CMP) Jumps: Why Investors Are Watching This Medical Technology StockCompumedics (ASX:CMP), an Australian medical technology company specializing in sleep and neurological diagnostics, saw its shares jump approximately 14% in recent trading, attracting renewed investor attention. The company reported trailing twelve-month revenue of A$58.5 million, up roughly 23.5%, marking a return to stronger top-line growth after flat performance in fiscal 2025 when it posted a small net loss of approximately A$1.3 million. Key growth catalysts include international contract wins in China and the Somfit wearable home-diagnostics device, though the earnings recovery remains early and unproven.AInvestCompumedics: Record Revenue and SaaS Scale Look Good, But The Stock Has A Valuation ProblemCompumedics reported record FY25 revenue of $51 million AUD and returned to profitability with $2.9 million EBITDA after years of losses, with first-half FY26 revenue of $31 million up 32% year-over-year. The company's shares have fallen 42% from their 52-week high of AU$0.45 to approximately AU$0.26, trading at 3-4 times forward sales on $70 million FY26 revenue guidance, raising questions about valuation sustainability. The analysis suggests investors should wait for FY26 full-year results to confirm whether the company can deliver on its guidance before establishing positions.ChannelLife AustraliaCompumedics wins AUD $4.2m MEG order in Chinese dealCompumedics has secured an approximately AUD $4.2 million sales order for an Orion LifeSpan magnetoencephalography system from Shandong Normal University in China, facilitated through its distributor Beijing Fistar. This order represents the sixth MEG system sold by the company, bringing total contracted MEG orders to approximately AUD $30 million, with revenue expected to be recognized in FY27. The company noted that China continues to show demand for advanced neuroscience research infrastructure and it maintains a pipeline of MEG opportunities across China, North America, and Europe.GlobeNewswireBrain Monitoring Research Report 2026 - Global Market Size, Trends, Competitive Analysis, Opportunities, and Forecasts, 2021-2025 & 2026-2031ResearchAndMarkets.com released a comprehensive market report projecting the Global Brain Monitoring Market to grow from USD 3.78 billion in 2025 to USD 5.57 billion by 2031, reflecting a CAGR of 6.69%, driven by aging populations and rising neurological disease prevalence. The report highlights key industry players including Medtronic (which reported $9.4 billion in Neuroscience revenue in 2024) and emerging companies like Ceribell (48% revenue growth to $17.2 million) and Compumedics (record $49.7 million revenues), as well as Alto Neuroscience's $128.6 million IPO. Market growth faces constraints from high system costs, complex reimbursement frameworks, and a critical global shortage of trained neurologists, with low-income nations having up to 82 times fewer specialists per capita compared to high-income countries.GlobeNewswireUnited States Sleep Apnea Devices Market Research and Competitive Analysis 2025-2033 Featuring Carefusion, Somnomed, ResMed, Koninklijke Philips, Compumedics, Natus Medical, Teleflex, Fisher & PaykelThe U.S. sleep apnea devices market is projected to grow from $2.16 billion in 2024 to $4.02 billion by 2033, a 7.14% CAGR. Growth is driven by rising prevalence, lifestyle factors, and demand for CPAP and BiPAP devices, while high costs and limited reimbursement pose barriers.YahooUnited States Sleep Apnea Devices Market Research and Competitive Analysis 2025-2033 Featuring Carefusion, Somnomed, ResMed, Koninklijke Philips, Compumedics, Natus Medical, Teleflex, Fisher & PaykelThe U.S. sleep apnea devices market is projected to grow from $2.16 billion in 2024 to $4.02 billion by 2033, a 7.14% CAGR. Growth is driven by rising prevalence, CPAP and BiPAP demand, and home healthcare, while high costs and limited reimbursement pose barriers.AijournEEG and EMG Devices Market to Grow by USD 793.5 Million (2024-2028) as Rising Neurological Conditions Drive Demand, AI Impact on Market Trends – Technavio ReportTechnavio reports that the global EEG and EMG devices market is projected to grow by USD 793.5 million between 2024 and 2028, driven by the rising prevalence of neurological conditions and the adoption of hybrid brain-computer interface technologies. The market is expected to expand at a CAGR of approximately 7.84%, although high costs associated with procedures and equipment pose significant challenges to widespread adoption. Key industry players identified in this sector include Medtronic Plc, Koninklijke Philips N.V., General Electric Co., and Compumedics Ltd.PR NewswireTranscranial Doppler Market size to grow by USD 39.74 million from 2023-2028| Atys Medical, Compumedics Ltd., ELCAT GmbH, General Electric Co., and more among the key companies in the market- TechnaviTechnavio announced that the global Transcranial Doppler Market is projected to grow by USD 39.74 million from 2023 to 2028, accelerating at a CAGR of 6.3%. The report identifies key market drivers such as the increased use of these systems for sickle cell disease detection and the rising demand for intraoperative brain monitoring. North America is expected to play a significant role in this growth, contributing approximately 41% to the market expansion.